查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1765417

全球罕見血液學市場

Rare Hematology
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計到 2030 年全球罕見血液學市場規模將達到 253 億美元

全球罕見血液學市場規模預計在2024年為190億美元，預計到2030年將達到253億美元，2024年至2030年的複合年成長率為4.9%。血漿衍生因子是本報告分析的細分市場之一，預計其複合年成長率為5.0%，到分析期結束時規模將達到182億美元。重組因子細分市場在分析期間內的複合年成長率預計為4.6%。

美國市場規模估計為 52 億美元，中國市場預期複合年成長率為 4.6%

美國罕見血液學市場規模預計在2024年達到52億美元。作為世界第二大經濟體，中國市場規模預計到2030年將達到40億美元，在2024-2030年的分析期間內，複合年成長率為4.6%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為4.2%。在歐洲，預計德國市場的複合年成長率為3.6%。

全球罕見血液學市場—主要趨勢和促進因素摘要

什麼是稀有血液學市場？為什麼它在醫療保健領域發展勢頭強勁？

罕見血液疾病市場專注於罕見血液疾病的診斷、治療和管理，包括血友病、鐮狀細胞疾病、地中海貧血、陣發性夜間血尿症(PNH) 和各種貧血等疾病。這些疾病被歸類為罕見疾病，因為它們僅影響全球一小部分人口，通常每 2,000 人中不到 1 人。儘管每種罕見血液疾病的患者數量相對較少，但由於其慢性病性質、複雜的管理要求和高昂的治療費用，這些疾病對醫療保健系統的累積影響巨大。傳統上，罕見血液疾病患者的治療選擇有限，研究投入也較低。然而，基因組學、生物技術和個人化醫療的最新趨勢正在改變這種狀況，導致旨在發現新治療方法和改善患者預後的研發活動激增。因此，由於人們意識的提高、支持性政策的訂定以及最先進治療的引入，罕見血液疾病市場正在獲得發展動力，這些因素正在重塑對這些挑戰的管理。

患者權益團體的興起以及醫療服務提供者、製藥公司和監管機構之間合作的加強也促進了罕見血液學市場的成長。國家罕見疾病組織 (NORD) 和歐洲血液學協會 (EHA) 等組織在倡導增加研究資金、改善治療機會和加強患者照護發揮了重要作用。這些努力鼓勵製藥公司投資開發治療罕見疾病的孤兒藥，儘管市場規模很小。世界各國政府推出了各種獎勵，包括市場獨佔權、稅額扣抵和加速核准流程，以鼓勵開發這些專門治療方法。因此，罕見血液學市場正在穩步湧入新的治療選擇，從基因療法和單株抗體到先進的生技藥品。這些創新解決方案的出現提高了醫療服務提供者管理罕見血液疾病的能力，改善了先前治療選擇有限或沒有治療選擇的患者的生活品質。

科技進步如何改變罕見血液疾病治療模式？

技術進步在罕見血液疾病治療方法的發展中發揮了變革性作用，徹底改變了這些疾病的診斷和治療方法。該領域最具突破性的創新之一是基因治療的出現。基因治療針對導致許多罕見血液疾病的潛在基因突變，提供了長期治療甚至根治性的可能性。例如，在治療血友病時，基因療法旨在透過引入缺陷基因的功能性拷貝來減少或消除對常規凝血因子替代療法的需要，使患者能夠自然產生必要的凝血因子。同樣，CRISPR-Cas9 等基因編輯技術正在被研究作為鐮狀細胞疾病和BETA地中海貧血的潛在治療方法，並在早期臨床試驗中取得了令人鼓舞的結果。這些技術有可能改變罕見血液疾病的治療模式，為傳統上依賴對症治療的患者帶來希望。

除了基因治療，生物製藥和標靶治療藥物的進展也擴大了罕見血液疾病的治療選擇。例如，單株抗體已被開發用於靶向作用於參與疾病進展的特定路徑和蛋白質，從而提供更精準的治療方法並減少副作用。在諸如陣發性尿失禁（PNH）等疾病中，補體抑制劑等標靶治療已被引入，以有效降低溶血和血栓症的風險，顯著改善患者的預後。此外，個人化醫療與罕見血液疾病的結合使醫療服務提供者能夠根據個體的基因圖譜制定治療方案，從而確保更高的療效和安全性。診斷技術也在不斷發展，次世代定序儀（NGS）和高通量篩檢方法能夠更準確、更快速地識別罕見基因突變。這些技術進步不僅有助於提高診斷的準確性，而且有助於早期發現和早期療育，有助於更有效地管理罕見血液疾病。

哪些因素將推動罕見血液學市場採用新治療方法？

有幾個因素促使罕見血液學市場擴大採用新療法，包括罕見血液病患疾病率的上升、醫學研究的進步以及有利的法規結構。罕見血液病患疾病率的上升部分歸因於診斷能力的提高，這使得這些疾病的檢測率更高、分類更準確。隨著越來越多的患者得到準確診斷，對超越傳統治療方法的創新療法的需求也在增加。同時，醫學研究的進步，特別是在基因組學和生物技術領域的進步，使得開發更有效、更有針對性的治療方法成為可能。這些治療方法在臨床試驗中的成功鼓勵製藥公司大力投資罕見血液學，為患者帶來更多新的和改進的治療方法選擇。

推動治療方法應用的另一個關鍵因素是法規環境的改善。美國食品藥物管理局(FDA) 和歐洲藥品管理局 (EMA) 等監管機構已意識到開發罕見疾病治療方法所面臨的獨特挑戰，並設立了孤兒藥地位和突破性療法認定等特殊稱號。這些制度提供獎勵，例如更長的市場獨佔期、更快的審查流程和降低的監管費用，從而對公司在罕見血液學領域進行藥物開發更具吸引力。此外，患者權益團體的影響力日益增強，提高了人們對可用治療方法的認知並擴大了資訊的獲取管道，使患者及其家屬能夠尋求專門護理和新治療方法。因此，這些新治療方法越來越受到認可，尤其是在先前治療選擇有限或根本沒有治療方法選擇的患者群體中。這些因素共同推動了更高的採用率，並擴大了新治療方法在罕見血液學市場的覆蓋範圍。

是什麼推動了全球罕見血液學市場的成長？

全球罕見血液學市場的成長受到多種因素的推動，包括對罕見疾病研究的日益關注、治療技術的進步以及不斷發展的醫療保健政策。主要成長要素之一是製藥和生技公司不斷增加的研發投資。在有利的監管激勵措施和不斷成長的患者需求的推動下，公司正在投入大量資源來發現和開發針對罕見血液疾病的創新治療方法。因此，新型療法正在穩步發展，從基因治療藥物和酵素替代藥物到下一代生技藥品和小分子藥物。市場也受益於技術進步，使得更有效的疾病建模、藥物篩檢和臨床試驗成為可能，從而加快了開發進程並更快地將新治療方法推向市場。

不斷發展的醫療政策也是市場成長的關鍵驅動力。許多國家都推出了全國罕見疾病計畫和政策，旨在改善罕見疾病（包括血液疾病）患者的診斷、治療和照護。這些政策通常包括增加研究經費、支持專科醫療中心發展以及改善患者獲得先進療法的途徑等措施。此外，學術界、產業界和患者組織之間的合作營造了更具協作性的研究環境，並加快了該領域的創新步伐。另一個成長要素是罕見血液疾病的增多，這反過來又導致需要專科治療的患者數量增加。認知度的提高和診斷能力的提高促進了診斷率的提高，進而推動了對標靶治療和綜合護理解決方案的需求。在這些因素的共同作用下，全球罕見血液疾病市場有望持續成長，這得益於強大的創新管道、強化的法律規範以及對改善患者預後和生活品質日益成長的關注。

部分

產品類型（血漿衍生因子、重組因子）、年齡層（成人（18歲以上））、兒童（0-17歲）

受訪公司範例

  • Alexion Pharmaceuticals, Inc.
  • Bayer Healthcare AG
  • CSL Behring
  • Novo Nordisk A/S
  • PRA Health Sciences
  • Shire PLC

人工智慧整合

我們正在利用可操作的專家內容和人工智慧工具來改變市場和競爭情報。

Global 特定產業SLM 的典型規範，而是建立了一個從全球專家收集的內容庫，其中包括視訊錄影、部落格、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地、進出口狀況（成品和原始OEM）預測其競爭態勢的變化。這種複雜且多面向的市場動態預計將以多種方式影響競爭對手，包括銷貨成本成本 (COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他地區

第4章 比賽

簡介目錄
Product Code: MCP16742

Global Rare Hematology Market to Reach US$25.3 Billion by 2030

The global market for Rare Hematology estimated at US$19.0 Billion in the year 2024, is expected to reach US$25.3 Billion by 2030, growing at a CAGR of 4.9% over the analysis period 2024-2030. Plasma Derived Factors, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$18.2 Billion by the end of the analysis period. Growth in the Recombinant Factors segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.2 Billion While China is Forecast to Grow at 4.6% CAGR

The Rare Hematology market in the U.S. is estimated at US$5.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.0 Billion by the year 2030 trailing a CAGR of 4.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.2% and 4.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Rare Hematology Market - Key Trends & Drivers Summarized

What Is The Rare Hematology Market and Why Is It Gaining Momentum in Healthcare?

The Rare Hematology market focuses on the diagnosis, treatment, and management of rare blood disorders, which include conditions such as hemophilia, sickle cell disease, thalassemia, paroxysmal nocturnal hemoglobinuria (PNH), and various types of anemia. These diseases are classified as rare because they affect a small percentage of the global population, typically less than 1 in 2,000 individuals. Although the patient population for each rare hematologic condition is relatively small, the cumulative impact of these diseases on healthcare systems is significant due to their chronic nature, complex management requirements, and the high cost of treatments. Traditionally, patients with rare hematologic conditions have faced limited treatment options and low levels of research investment. However, recent advancements in genomics, biotechnology, and personalized medicine are changing this scenario, leading to a surge in research and development activities aimed at discovering novel therapies and improving patient outcomes. As a result, the Rare Hematology market is gaining momentum, driven by increasing awareness, supportive policies, and the introduction of cutting-edge treatments that are reshaping the management of these challenging conditions.

The rise of patient advocacy groups and increased collaboration between healthcare providers, pharmaceutical companies, and regulatory bodies have also contributed to the growth of the Rare Hematology market. Organizations such as the National Organization for Rare Disorders (NORD) and the European Hematology Association (EHA) have been instrumental in advocating for more research funding, better access to treatments, and enhanced patient care. These efforts have spurred pharmaceutical companies to invest in the development of orphan drugs-medications designed to treat rare conditions-despite the smaller market size. Governments around the world have introduced various incentives, including market exclusivity, tax credits, and fast-track approval processes, to encourage the development of these specialized treatments. As a result, the Rare Hematology market has seen a steady influx of new therapeutic options, ranging from gene therapies and monoclonal antibodies to advanced biologics. With the advent of these innovative solutions, healthcare providers are better equipped to manage rare hematologic disorders, improving the quality of life for patients who previously had limited or no treatment options.

How Are Technological Advancements Transforming The Treatment Landscape Of Rare Hematologic Disorders?

Technological advancements have played a transformative role in the development of therapies for rare hematologic disorders, revolutionizing the way these diseases are diagnosed and treated. One of the most groundbreaking innovations in this field is the advent of gene therapy. Gene therapies target the underlying genetic mutations responsible for many rare blood disorders, offering the potential for long-term or even curative treatments. For example, in the treatment of hemophilia, gene therapies aim to introduce a functional copy of the defective gene, enabling patients to produce the necessary clotting factors naturally, thereby reducing or eliminating the need for regular factor replacement therapy. Similarly, gene-editing technologies such as CRISPR-Cas9 are being explored as potential treatments for sickle cell disease and beta-thalassemia, with early clinical trials showing promising results. These technologies have the potential to transform the treatment paradigm for rare hematologic disorders, offering hope for patients who have historically relied on symptomatic treatments.

In addition to gene therapy, advances in biologics and targeted therapies are expanding the range of treatment options available for rare hematologic conditions. Monoclonal antibodies, for instance, have been developed to target specific pathways or proteins involved in disease progression, offering a more precise approach to treatment with fewer side effects. For conditions like PNH, targeted therapies such as complement inhibitors have been introduced, which effectively reduce hemolysis and the risk of thrombosis, significantly improving patient outcomes. Furthermore, the integration of personalized medicine into rare hematology is enabling healthcare providers to tailor treatments based on individual genetic profiles, ensuring a higher degree of efficacy and safety. Diagnostic technologies are also evolving, with next-generation sequencing (NGS) and high-throughput screening methods making it possible to identify rare genetic mutations with greater accuracy and speed. These technological advancements are not only enhancing the precision of diagnoses but also facilitating earlier detection and intervention, which are crucial for managing rare hematologic disorders more effectively.

What Factors Are Driving The Adoption Of New Treatments In The Rare Hematology Market?

Several factors are contributing to the increased adoption of new treatments in the Rare Hematology market, including the growing prevalence of rare blood disorders, advancements in medical research, and favorable regulatory frameworks. The rising incidence of rare hematologic conditions is partly due to improved diagnostic capabilities, which have led to higher detection rates and more accurate classification of these diseases. With more patients being accurately diagnosed, there is a greater demand for innovative therapies that go beyond conventional treatments. At the same time, advancements in medical research, particularly in the fields of genomics and biotechnology, are enabling the development of more effective and targeted therapies. The success of these therapies in clinical trials has spurred pharmaceutical companies to invest heavily in rare hematology, leading to an increase in the availability of new and improved treatment options for patients.

Another key driver of treatment adoption is the supportive regulatory environment. Recognizing the unique challenges associated with developing therapies for rare diseases, regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have established special designations like Orphan Drug Status and Breakthrough Therapy Designation. These programs provide incentives such as extended market exclusivity, expedited review processes, and reduced regulatory fees, making it more attractive for companies to pursue drug development in the rare hematology space. Additionally, the growing influence of patient advocacy groups has led to increased awareness and better access to information about available treatments, empowering patients and their families to seek out specialized care and novel therapies. As a result, there is a rising acceptance of these new treatments, especially among patient populations that previously had limited or no therapeutic options. The combination of these factors is driving higher adoption rates and expanding the reach of new therapies within the Rare Hematology market.

What Is Driving The Growth Of The Global Rare Hematology Market?

The growth in the global Rare Hematology market is driven by several factors, including the increased focus on rare disease research, advancements in therapeutic technologies, and evolving healthcare policies. One of the primary growth drivers is the rising investment in research and development by pharmaceutical and biotechnology companies. Encouraged by favorable regulatory incentives and growing patient demand, companies are dedicating substantial resources to the discovery and development of innovative therapies for rare blood disorders. This has led to a steady pipeline of new treatments, ranging from gene therapies and enzyme replacements to next-generation biologics and small molecule drugs. The market is also benefiting from technological innovations that are enabling more effective disease modeling, drug screening, and clinical trials, thereby accelerating the development process and bringing new therapies to market more quickly.

Evolving healthcare policies are another crucial driver of market growth. Many countries have introduced national rare disease plans or policies aimed at improving the diagnosis, treatment, and care of patients with rare diseases, including hematologic conditions. These policies often include initiatives to increase research funding, support the development of specialized care centers, and improve patient access to advanced therapies. Furthermore, collaborations between academia, industry, and patient organizations are fostering a more collaborative research environment, accelerating the pace of innovation in the field. Another growth driver is the increasing prevalence of rare hematologic conditions, which is creating a larger patient pool in need of specialized treatments. Improved awareness and better diagnostic capabilities are contributing to higher diagnosis rates, which in turn are driving demand for targeted therapies and comprehensive care solutions. As these factors converge, the global Rare Hematology market is poised for continued growth, supported by a strong innovation pipeline, enhanced regulatory frameworks, and an ever-increasing focus on improving patient outcomes and quality of life.

SCOPE OF STUDY:

The report analyzes the Rare Hematology market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Plasma Derived Factors, Recombinant Factors); Age Group (Adult (18+), Pediatric (0-17))

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • Alexion Pharmaceuticals, Inc.
  • Bayer Healthcare AG
  • CSL Behring
  • Novo Nordisk A/S
  • PRA Health Sciences
  • Shire PLC

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Rare Hematology - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Awareness of Rare Blood Disorders Spurs Growth of the Rare Hematology Market
    • Rising Investment in Orphan Drug Development Strengthens Business Case for Rare Hematology Therapeutics
    • Advancements in Gene and Cell Therapy Propel Innovation in Rare Hematology Treatments
    • Development of Innovative Therapeutics for Hemophilia Drives Market Demand
    • Focus on Expanding Treatment Options for Sickle Cell Disease Accelerates Market Growth
    • Development of Novel Biomarkers for Blood Disorders Expands Scope of Rare Hematology Treatments
    • Emergence of Stem Cell Therapies Bodes Well for Market Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Rare Hematology Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Rare Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Rare Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Rare Hematology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Plasma Derived Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Plasma Derived Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Plasma Derived Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Recombinant Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Recombinant Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Recombinant Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Adult (18+) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Adult (18+) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Adult (18+) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pediatric (0-17) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Pediatric (0-17) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Pediatric (0-17) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Rare Hematology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: USA 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: Canada 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030
  • JAPAN
    • Rare Hematology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Japan 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030
  • CHINA
    • Rare Hematology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: China 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030
  • EUROPE
    • Rare Hematology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Rare Hematology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Rare Hematology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Europe 15-Year Perspective for Rare Hematology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030
  • FRANCE
    • Rare Hematology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: France 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030
  • GERMANY
    • Rare Hematology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Germany 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Italy 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Rare Hematology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: UK 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 74: Rest of Europe Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Rest of Europe Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Rest of Europe 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Rest of Europe Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Rest of Europe 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Rare Hematology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 80: Asia-Pacific Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Asia-Pacific Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Asia-Pacific 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Asia-Pacific Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Asia-Pacific 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 86: Rest of World Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of World Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Rest of World 15-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2015, 2025 & 2030
    • TABLE 89: Rest of World Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of World Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of World 15-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2015, 2025 & 2030

IV. COMPETITION